Lecointe Joiliana, Gan Sushrima, Tripathi Dipti, Ichimura Shoko, Clouthier Katie L, Kushwaha Ankit, Mercer-Rosa Laura, Reddy Sushma
School of Medicine, Meharry Medical College, Nashville, TN (J.L.).
Department of Pediatrics (Cardiology) and Cardiovascular Institute (S.G., S.I., A.K., S.R.), Stanford University, Palo Alto, CA.
Circ Heart Fail. 2025 May;18(5):e012136. doi: 10.1161/CIRCHEARTFAILURE.124.012136. Epub 2025 Apr 16.
Single ventricle congenital heart disease like hypoplastic left heart syndrome with a Fontan circulation constitutes, the largest group of children hospitalized with circulation failure, experiencing an in-hospital mortality rate of 20% to 50%. We investigated the mechanisms leading to Fontan failure to identify novel therapeutic targets.
Blood was collected from patients with hypoplastic left heart syndrome post-Fontan and controls (n=6/group). Plasma microvesicles were isolated, and proteomics assessed using data-independent acquisition mass spectroscopy. Dysregulated proteins with a fold change >1.5 or ≤1.5, <0.05, were evaluated using the Database for Annotation, Visualization, and Integrated Discovery and Ingenuity pathway analysis. Correlation of highly dysregulated proteins was assessed with New York Heart Association class, right ventricular fractional area change, oxygen saturation, and hemoglobin.
The age of Fontan patients versus controls was 16.0±2.1 versus 15.3±2.2. Three of 6 Fontan patients were in New York Heart Association class II, and 3 of 6 were in New York Heart Association III/IV; 4 of 6 had Fontan-associated liver disease. Overall, 72 proteins were upregulated, and 187 proteins were downregulated in Fontan failure. Proteins upregulated in Fontan failure predicted cell death pathways (Solute carrier family 2, Angiotensinogen, CD14) and mitochondrial reactive oxygen species signaling (ATP5F1A, S100A8); downregulated proteins predicted impaired cell survival (tyrosine-protein kinase, endothelial growth factors) and mitochondrial antioxidant enzymes (GPX1, PRDX5) Increasing expression of the following proteins was associated with worsening New York Heart Association class, ventricular function and cyanosis: complement system (C1QA, =0.91), mitochondrial reactive oxygen species generation (HSPD1, =0.81; ATP5F1A, =0.75), and cytoskeletal proteins (ANK1, =0.63; ACTN1, =0.76).
Proteins from circulating microvesicles from patients with hypoplastic left heart syndrome post-Fontan are mostly from the liver. While this pilot study is limited by its sample size and may not represent the broader Fontan population, the proteomic changes were associated with worsening heart failure and cyanosis, suggesting their potential utility as biomarkers.
单心室先天性心脏病,如伴有Fontan循环的左心发育不全综合征,是因循环衰竭住院儿童中最大的群体,其院内死亡率为20%至50%。我们研究了导致Fontan失败的机制,以确定新的治疗靶点。
收集Fontan术后左心发育不全综合征患者及对照组(每组n = 6)的血液。分离血浆微泡,使用数据非依赖采集质谱法评估蛋白质组学。使用注释、可视化和综合发现数据库以及 Ingenuity 通路分析对变化倍数>1.5或≤1.5且P<0.05的失调蛋白进行评估。评估高度失调蛋白与纽约心脏协会分级、右心室分数面积变化、氧饱和度和血红蛋白的相关性。
Fontan患者与对照组的年龄分别为16.0±2.1岁和15.3±2.2岁。6例Fontan患者中3例为纽约心脏协会II级,6例中3例为纽约心脏协会III/IV级;6例中有4例患有Fontan相关肝病。总体而言,Fontan失败患者中有72种蛋白质上调,187种蛋白质下调。Fontan失败中上调的蛋白质预测细胞死亡途径(溶质载体家族2、血管紧张素原、CD14)和线粒体活性氧信号传导(ATP5F1A、S100A8);下调的蛋白质预测细胞存活受损(酪氨酸蛋白激酶、内皮生长因子)和线粒体抗氧化酶(GPX1、PRDX5)。以下蛋白质表达增加与纽约心脏协会分级恶化、心室功能和紫绀相关:补体系统(C1QA,r = 0.91)、线粒体活性氧生成(HSPD1,r = 0.81;ATP5F1A,r = 0.75)和细胞骨架蛋白(ANK1,r = 0.63;ACTN1,r = 0.76)结论:Fontan术后左心发育不全综合征患者循环微泡中的蛋白质大多来自肝脏。虽然这项初步研究受样本量限制,可能不代表更广泛的Fontan人群,但蛋白质组学变化与心力衰竭和紫绀恶化相关,表明它们作为生物标志物的潜在效用。